Crisaborole is a PDE4 inhibitor. PDE4 activity is increased in circulating inflammatory cells in patients with atopic dermatitis. PDE4 is a very core regulatory point for the production of inflammatory cytokines in atopic dermatitis, mainly through the degradation of cyclic adenosine monophosphate.